HSBC Holdings’s Gyre Therapeutics GYRE Stock Holding History

HSBC Holdings’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,169	Closed	-$15.7K	–	2799
2023 Q3	$15.7K	Hold	2,169	–	–	﹤0.01%	2677
2023 Q2	$11.5K	Hold	2,169	–	–	﹤0.01%	2532
2023 Q1	$6.75K	Sell	2,169 -2,168	-50%	-$8.24K	﹤0.01%	2629
2022 Q4	$17.1K	Hold	4,337	–	–	﹤0.01%	3021
2022 Q3	$17K	Hold	4,337	–	–	﹤0.01%	2876
2022 Q2	$57K	Hold	4,337	–	–	﹤0.01%	3122
2022 Q1	$22K	Hold	4,337	–	–	﹤0.01%	3233
2021 Q4	$30K	Hold	4,337	–	–	﹤0.01%	3222
2021 Q3	$134K	Hold	4,337	–	–	﹤0.01%	2851
2021 Q2	$141K	Buy	4,337 +678	+19%	+$23.3K	﹤0.01%	2812
2021 Q1	$139K	Buy	3,659 +683	+23%	+$31.2K	﹤0.01%	2599
2020 Q4	$138K	Buy	2,976 +76	+3%	+$3.29K	﹤0.01%	2901
2020 Q3	$97K	Buy	2,900 +1,402	+94%	+$54.9K	﹤0.01%	2623
2020 Q2	$66K	Buy	+1,498	New	+$70.3K	﹤0.01%	2562

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HSBC Holdings's GYRE Position: Q4 2023 in Review

HSBC Holdings sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 2,169 shares — an estimated $15.7K sold.

HSBC Holdings first reported a position in GYRE in Q2 2020 and held it in 14 quarters. The position peaked at $141K in Q2 2021. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

HSBC Holdings reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
HSBC Holdings sold 2,169 Gyre Therapeutics shares in Q4 2023, an estimated $15.7K.
HSBC Holdings first reported a position in Gyre Therapeutics in Q2 2020 and held it in 14 quarters.
HSBC Holdings's Gyre Therapeutics position peaked at $141K in Q2 2021.
16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on HSBC Holdings's 13F filing for Q4 2023, filed 12 Feb 2024.